Cellular and genetic therapies for haemophilia
Open Access
- 27 April 2006
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 12 (s3) , 36-41
- https://doi.org/10.1111/j.1365-2516.2006.01259.x
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapyBlood, 2005
- Development and characterization of a cell line for large‐scale, serum‐free production of recombinant adeno‐associated viral vectorsThe Journal of Gene Medicine, 2004
- Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site PreferencesPLoS Biology, 2004
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003
- Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vectorBlood, 2003
- Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectorsBlood, 2003
- Site-specific genomic integration produces therapeutic Factor IX levels in miceNature Biotechnology, 2002
- Dangerous liaisons: the role of “danger” signals in the immune response to gene therapyBlood, 2002
- A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacsJournal of Internal Medicine, 1994
- Characterization of the human factor VIII geneNature, 1984